PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

November 30, 2017

Conditions
Malaria
Interventions
BIOLOGICAL

PfSPZ Vaccine

Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites

BIOLOGICAL

CHMI (7G8)

CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.

BIOLOGICAL

CHMI (NF135.C10)

CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.

Trial Locations (2)

20910

Naval Medical Research Center, Silver Spring

21201

University of Maryland-Baltimore, Center for Vaccine Development, Baltimore

Sponsors
All Listed Sponsors
collaborator

Naval Medical Research Center

FED

collaborator

University of Maryland

OTHER

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

Joint Warfighter Medical Research Program

OTHER

lead

Sanaria Inc.

INDUSTRY

NCT02601716 - PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults | Biotech Hunter | Biotech Hunter